Iron-Chelating Therapy

References

• Easley R. M., Schreiner B. F., Yu P. N. Reversible cardiomyopathy associated with hemochromatosis. N. Engl. J. Med. 1972; 287: 866
   Google Scholar
• Short E. M., Winkle R. A., Billingham M. E. Myocardial involvement in idiopathic hemochromatosis—morphologic and clinical improvement following venesection. Am. J. Med. 1981; 70: 1275
   Google Scholar
• Wohler F. The treatment of haemochromatosis with desferioxamine. Acta Haematol. 1963; 30: 65
   PubMedGoogle Scholar
• Keberle H. The biochemistry of desferoxamine and its relation to iron metabolism. Ann. NY. Acad. Sci. 1964; 119: 758
   PubMed Web of Science ®Google Scholar
• Peters G., Keberle H., Schmid K., Brunner H. Distribution and renal excretion of desferrioxamine and ferrioxamine in the dog and in the rat. Biochem. Pharmacol. 1966; 15: 93
   PubMed Web of Science ®Google Scholar
• Meyer-Brunot H. G., Keberle H. The metabolism of desferrioxamine B. Biochem. Pharmacol. 1967; 16: 527
   Google Scholar
• Barry M., Flynn D. M., Letsky E. A., Risdon R. A. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology and clinical progress. Br. Med. J. 1974; 2: 16
   PubMed Web of Science ®Google Scholar
• Buja L. M., Roberts W. C. Iron in the heart: etiology and clinical significance. Am. J. Med. 1971; 51: 209
   PubMed Web of Science ®Google Scholar
• Engle M. A., Erlandson M., Smith C. H. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964; 30: 698
   PubMed Web of Science ®Google Scholar
• Brown E. B., Dubach R., Smith D. E. Studies in iron transportation and metabolism. X. Long term iron overload in dogs. J. Lab. Clin. Med. 1957; 50: 862
   PubMedGoogle Scholar
• Awai M., Narasaki M., Yamanoi Y., Seno S. Induction of diabetes in animals by parenteral administration of ferric nitriloacetate. Am. J. Pathol 1979; 95: 663
   PubMed Web of Science ®Google Scholar
• Editorial. Metal chelation therapy, oxygen radicals, and human disease. Lancet 1985; 1: 143
   PubMed Web of Science ®Google Scholar
• Halliwell B., Gutteridge M. C. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 1984; 219: 1
   PubMed Web of Science ®Google Scholar
• Slivka A., Kang J., Cohen G. Hydroxyl radicals and the toxicity of oral iron. Biochem. Pharmacol. 1986; 35: 553
   PubMed Web of Science ®Google Scholar
• Starke P. E., Farber J. L. Ferric iron and superoxide ions are required for the killing of cultured hepatocytes by hydrogen peroxide. J. Biol. Chem. 1985; 260: 10099
   PubMed Web of Science ®Google Scholar
• Sutton H. C. Efficiency of chelated iron compounds as catalysts for the Haber-Weiss reaction. J. Free Radical Biol. Med. 1985; 1: 195
   PubMedGoogle Scholar
• Baker M. S., Gebicki J. M. The effect of pH on yields of hydroxyl radicals produced from superoxide by potential biological Eiron chelators. Arch. Biochem. Biophys. 1986; 246: 581
   PubMed Web of Science ®Google Scholar
• Heys A. D., Dormandy T. L. Lipid peroxidation in iron loaded spleens. Clin. Sci. 1981; 60: 295
   Web of Science ®Google Scholar
• Hultcrantz R., Ericsson J. L. E., Hirth T. Levels of malondialdehyde production in rat liver following loading and unloading with iron. Virchow's Arch. 1984; 45: 139
   Web of Science ®Google Scholar
• Yamanoi Y., Matsuura R., Awai M. Mechanism of iron toxicity in the liver and pancreas after a single injection of ferric nitriloacetate. Acta Haematol. Jpn. 1982; 45: 1229
   PubMedGoogle Scholar
• Hanstein W. G., Sacks P. V., Muller-Eberhard U. Properties of liver mitochondria from iron-loaded rats. Biochem. Biophys. Res. Commun. 1975; 67: 1175
   PubMed Web of Science ®Google Scholar
• Goddard J. G., Sweeney G. D.M. Ferric nitriloacetate: a potent stimulant of in vivo lipid peroxidation in mice. Biochem. Pharmacol. 1983; 32: 3879
   PubMed Web of Science ®Google Scholar
• Dillard C. J., Downey E.-J., Tappel A. L. Effect of antioxidants on lipid peroxidation in iron-loaded rats. Lipids 1984; 19: 127
   PubMed Web of Science ®Google Scholar
• Ganote C. E., Nahara G. Acute ferrous sulfate hepatotoxicity in rats. An electron microscopic and biochemical study. Lab. Invest. 1973; 28: 426
   PubMed Web of Science ®Google Scholar
• Reissmann K. R., Coleman T. J. Acute intestinal iron intoxication. II. Metabolic, respiratory and circulatory effects of absorbed iron salts. Blood 1955; 10: 46
   PubMed Web of Science ®Google Scholar
• Iancu T. C., Shiloh H., Link G., Bauminger E. R., Pinson A., Hershko C. Ultrastructural pathology of iron-loaded rat myocardial cells in culture. Br. J. Exp. Pathol. 1987; 68: 53
   PubMedGoogle Scholar
• Bacon B. R., Park C. H., Brittenham G. M., O'Neill R., Tavill A. S. Hepatic mitochondrial oxidative metabolism in rats with chronic dietary iron overload. Hepatology 1985; 5: 789
   PubMed Web of Science ®Google Scholar
• Seymour C. A., Peters T. J. Organelle pathology in primary and secondary hemochromatosis with special reference to lysosomal changes. Br. J. Haematol. 1978; 40: 239
   PubMed Web of Science ®Google Scholar
• Weir M. P., Gibson J. F., Peters T. J. Haemosiderin and tissue damage. Cell Biochem. Function 1984; 2: 186
   PubMed Web of Science ®Google Scholar
• Fitchett D. H., Coltart D. J., Littler W. A., Leyland M. J., Trueman T., Gozzard D. J., Peters T. J. Cardiac involvement in secondary hemochromatosis: a catheter biopsy study and analysis of myocardium. Cardiovas. Res. 1980; 14: 719
   PubMed Web of Science ®Google Scholar
• O'Connell M. J., Ward R. J., Baum H., Peters T. J. The role of iron in ferritin-and haemosiderin-mediated lipid peroxidation in liposomes. Biochem. J. 1985; 229: 135
   PubMed Web of Science ®Google Scholar
• Laub R., Schneider Y. J., Octave J. N., Trouet A., Crichton R. R. Cellular pharmacology of deferrioxamine B and derivatives in cultured rat hepatocytes in relation to iron mobilization. Biochem. Pharmacol. 1985; 34: 1175
   PubMed Web of Science ®Google Scholar
• Hershko C., Peto T. E. A. Non-transferrin iron. Br. J. Haematol. 1987; 66: 149
   PubMed Web of Science ®Google Scholar
• Scott J. A., Ankhaw B., Locke E., Haber E., Homney C. The role of free radical-mediated processes in oxygen-related damage in cultured murine myocardial cells. Circ. Res. 1985; 56: 72
   PubMed Web of Science ®Google Scholar
• Moreb J., Hershko C., Hasin Y. Effects of acute iron loading on contractility and spontaneous beating rate of cultured rat myocardial cells, in press
   Google Scholar
• Hershko C. Storage iron regulation. Prog. Hemalol. 1977; 10: 105
   PubMedGoogle Scholar
• Drysdale J. W., Munro H. N. Regulation of synthesis and turnover of ferritin in rat liver. J. Biol. Chem. 1966; 241: 3630
   PubMed Web of Science ®Google Scholar
• Jacobs A., Hoy T., Humphrys J., Perera P. Iron overload in chang cell cultures: biochemical and morphological studies. Br. J. Exper. Pathol. 1978; 59: 489
   PubMedGoogle Scholar
• White G. P., Jacobs A. Iron uptake by chang cells from transferrin, nitriloacetate and citrate complexes. The effects of iron-loading and chelation witfi desferrioxamine. Biochim. Biophys. Acta 1978; 543: 217
   PubMedGoogle Scholar
• Link G., Pinson A., Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J. Lab. Clin. Med. 1985; 106: 147
   PubMed Web of Science ®Google Scholar
• Yamanoi Y., Awai M., Sewno S. Degranulation effect of ferric nitriloacetate (Fe3+-NTA) on the pancreatic islet β-cells: its acute toxic effect on glucose metabolism. Acta Med. Okayama 1984; 38: 423
   Google Scholar
• Awai M., Yamanoi Y., Kuwashima J., Seno S. Induction mechanism of diabetes by ferric nitriloacetate injection. The Biochemistry and Physiology of Iron, P. Saltman, J. Hegenauer. Elsevier/North Holland, Amsterdam 1982; 543
   Google Scholar
• Crouch R. K., Gandy S. E., Kimsey G., Galbraith R. A., Galbraith G. M. P., Buse M. G. The inhibition of islet superoxide dismutase by diabetogenic drugs. Diabetes 1981; 30: 235
   PubMed Web of Science ®Google Scholar
• Artman M., Olson R. D., Boerth R. C. Depression of myocardial contractility in acute iron toxicity in rabbits. Toxicol. Appl. Pharmacol. 1982; 66: 329
   PubMed Web of Science ®Google Scholar
• Artman M., Olson R. D., Boucek R. J., Ghisnan F. K., Boerth R. C. Acute effects of iron on contractile function in isolated rabbit myocardium. Dev. Pharmacol. Ther. 1984; 7: 50
   Google Scholar
• Byers B. R., Sciortino C. V., Cox P., Robinson P., Hillibert S. Iron transport and distribution in cultures of beating heart cells. The Biochemistry and Physiology of Iron, P. Saltmann, J. Hegenauer. Elsevier/North Holland, Amsterdam 1982; 179
   Google Scholar
• Sciortino C. V., Byers B. R., Cox P. Evaluation of iron-chelating agents in cultured heart muscle cells. Identification of a potential drug for chelation therapy. J. Lab. Clin. Med. 1980; 96: 1081
   Google Scholar
• Cox P. G., Harvey N. E., Sciortino C., Byers B. R. Electron-microscopic and radioiron studies of iron uptake in newborn rat myocardial cells in vitro. Am. J. Pathol. 1981; 102: 151
   Google Scholar
• Hershko C., Link G., Pinson A. Modification of iron uptake and lipid peroxidation by hypoxia, ascorbic acid and α-tocopherol in iron-loaded rat myocardial cell cultures. J. Lab. Clin. Med. 1987; 110: 355
   PubMed Web of Science ®Google Scholar
• Link G., Athias P., Grynberg A., Pinson A., Hershko C. Effect of iron loading on transmembrane potential, contraction and automaticity of rat ventricular muscle cells in culture, in preparation
   Google Scholar
• Wills E. D. Lipid peroxide formation in microsomes. The role of non-haem iron. Biochem.’. 1969; 13: 325
   Google Scholar
• Morehouse L. A., Thomas C. E., Aust S. D. Superoxide generation by NADPH-Cytochrome P-450 reductase: the effect of iron chelators and the role of superoxide in microsomal lipid peroxidation. Arch. Biochem. Biophys. 1984; 232: 366
   PubMed Web of Science ®Google Scholar
• Hoe S., Rowley D. A., Halliwell B. Reactions of ferrioxamine and desferrioxamine with the hydroxyl radical. Chem. Biol. Interact. 1982; 41: 75
   PubMed Web of Science ®Google Scholar
• Halliwell B. Use of desferrioxamine as a probe for iron dependent formation of hydroxyl radicals. Biochem. Pharmacol. 1985; 34: 229
   PubMed Web of Science ®Google Scholar
• Ley T. J., Griffith P., Nienhuis A. W. Transfusion haemosiderosis and chelation therapy. Clin. Haematol. 1982; 11: 437
   PubMedGoogle Scholar
• Modell B., Berdoukas V. The Clinical Approach to Thalassaemia. Grune & Stratton, New York 1984; 140
   Google Scholar
• Weatherall D. J., Clegg J. B. Thalassaemia Syndromes3rd ed. Blackwell Scientific, Oxford 1981
   Google Scholar
• Hoffbrand A. V. Transfusion siderosis and chelation therapy. Iron in Biochemistry and Medicine II, A. Jacobs, M. Worwood. Academic Press, New York 1980; 499
   Google Scholar
• Summers M. R., Jacobs A., Tudway D., Perera P., Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br. J. Haematol., 42: 547
   Google Scholar
• Hershko C., Rachmilewitz E. A. Mechanism of desferrioxamine-induced iron excretion in thalassaemia. Br. J. Haematol. 1979; 42: 125
   PubMedGoogle Scholar
• Callender S. T., Weatherall D. J. Iron chelation with oral desferrioxamihe. Lancet 1980; 2: 689
   Google Scholar
• Pippard M. J., Warner G. T., Callender S. T., Weatherall D. J. Iron absorption in iron-loading anaemias: effect of subcutaneous desferrioxamine infusions. Lancet 1977; 2: 739
   Google Scholar
• Hershko C., Cook J. D., Finch C. A. Storage iron kinetics. III. Study of desferoxamine action by selective radioiron labels of RE and parenchymal cells. J. Lab. Clin. Med. 1973; 81: 876
   PubMedGoogle Scholar
• Olsson K. S. Iron stores in normal men and male blood donors. Acta Med. Scand. 1972; 192: 401
   PubMedGoogle Scholar
• Hallberg L., Hedenberg L., Weinfeld A. Liver iron and desferrioxamine-induced iron excretion. Scand. J. Haematol. 1966; 3: 85
   Google Scholar
• Barry M. Iron and the liver. Gut 1974; 15: 324
   PubMed Web of Science ®Google Scholar
• Pippard M. J., Johnson D. K., Finch C. A. Hepatocyte iron kinetics in the rat explored with an iron chelator. Br. J. Haematol. 1982; 52: 211
   PubMed Web of Science ®Google Scholar
• Pippard M. J., Callender S. T., Finch C. A. Ferrioxamine excretion in iron-loaded man. Blood 1982; 60: 288
   PubMed Web of Science ®Google Scholar
• Cumming R. L. C., Goldberg A., Morrow J., Smith J. A. Effect of phenylhydrazine-induced haemolysis on the urinary excretion of iron after desferrioxamine. Lancet 1967; 1: 71
   Google Scholar
• Karabus C. D., Fielding J. Desferrioxamine chelatable iron in haemolytic, megaloblastic and sideroblastic anaemias. Br. J. Haematol. 1967; 13: 924
   PubMed Web of Science ®Google Scholar
• Lynch S. R., Lipschitz D. A., Bothwell T. H., Charlton R. W. Iron and the reticuloendothelial system. Iron in Biochemistry and Medicine, A. Jacobs, M. Worwood. Academic Press, New York 1974; 563
   Google Scholar
• Octave J. N., Schneider Y. J., Crichton R. R., Trouet A. Iron mobilization from cultured hepatocytes: effect of desferrioxamine B. Biochem. Pharmacol. 1983; 32: 3413
   PubMed Web of Science ®Google Scholar
• Esparza I., Brock J. H. Release of iron by resident macrophages following ingestion and degradation of transferrin-antitransferrin immune complexes. Br. J. Haematol. 1981; 49: 603
   PubMed Web of Science ®Google Scholar
• Cook J. D., Marsaglia G., Eschbach J. W. Ferrokinetics: a biologic model for plasma iron exchange in man. J. Clin. Invest. 1970; 49: 197
   Google Scholar
• Kim B. K., Huebers H., Pippard M. J., Finch C. A. Storage iron exchange in the rat as affected by desferrioxamine. J. Lab. Clin. Med. 1985; 105: 440
   PubMedGoogle Scholar
• Hershko C. A study of the chelating agent diethylenetriamine pentaacetic acid using selective radioiron probes of reticuloendothelial and parenchymal iron stores. J. Lab. Clin. Med. 1975; 85: 913
   PubMedGoogle Scholar
• Hershko C. Determinants of fecal and urinary iron excretion in desferrioxamine treated rats. Blood. 1978; 51: 415
   PubMed Web of Science ®Google Scholar
• Hershko C., Grady R. W., Cerami A. Mechanism of iron chelation in the hypertransfused rat: definition of the two alternative pathways of iron mobilization. J. Lab. Clin. Med. 1978; 92: 144
   Google Scholar
• Unger A., Hershko C. Hepatocellular uptake of ferritin in the rat. Br. J. Haematol. 1984; 28: 169
   Google Scholar
• Pippard M. J., Jackson M. J., Hoffman K., Petron M., Modell C. B. Iron chelation using subcutaneous infusions of diethylene triamine pentaacetic acid (DTPA). Scand. J. Haematol. 1986; 36: 466
   PubMedGoogle Scholar
• Hershko C., Graham G., Bates G. W., Rachmilewitz E. A. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br. J. Haematol. 1978; 40: 255
   PubMed Web of Science ®Google Scholar
• Batey R. G., Lai Chung Fong P., Sherlock S. The nature of serum iron in primary haemochromatosis. Clin. Sci. 1978; 55: 24
   Google Scholar
• Anuwatanakulchai M., Pootrakul P., Thuvasethakul P., Wasi P. Non-transferrin plasma iron in β-thalassaemia/HbE and haemoglobin H diseases. Scand. J. Haematol. 1984; 32: 153
   Google Scholar
• Wang W. C., Ahmed N., Hanna M. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias. J. Pediatr. 1986; 108: 552
   PubMed Web of Science ®Google Scholar
• Wagstaff M., Peters S. W., Jones B. M., Jacobs A. Free iron and iron toxicity in iron overload. Br. J. Haematol. 1985; 61: 566
   Google Scholar
• Gutteridge J. M. C., Rowley D. A., Griffiths E., Halliwell B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin. Sci. 1985; 68: 463
   PubMed Web of Science ®Google Scholar
• Sephton-Smith R. Iron excretion in thalassaemia major after administration of chelating agents. Br. Med. J. 1962; 2: 1577
   PubMedGoogle Scholar
• Sephton-Smith R. Chelating agents in the diagnosis and treatment of iron overload in thalassaemia. Ann. N.Y. Acad. Sci. 1964; 119: 776
   Google Scholar
• Bannerman R. M., Callender S. T., Williams D. L. Effect of desferrioxamine and DTPA in iron overload. Br. Med. J. 1962; 2: 1573
   Google Scholar
• Waxman H. S., Brown E. B. Clinical usefulness of chelating agents. Prog. Hematol. 1969; 6: 338
   Google Scholar
• Modell C. B., Beck J. Long-term desferrioxamine therapy in thalassaemia. Ann. N.Y. Acad. Sci. 1974; 232: 201
   PubMed Web of Science ®Google Scholar
• Wapnick A. A., Lynch S. R., Charlton R. B., Seftel H. C., Bothwell T. H. The effect of ascorbic acid deficiency on desferrioxamine induced urinary iron excretion. Br. J. Haematol. 1969; 17: 563
   PubMed Web of Science ®Google Scholar
• Propper R. D., Shurin S. B., Nathan D. G. Reassessment of the use of desferrioxamine B in iron overload. N. Engl. J. Med. 1976; 294: 1421
   PubMed Web of Science ®Google Scholar
• Graziano J. H., Markenson A., Miller D. R., Chang H., Bestak M., Meyers P., Pisciotto P., Rifkind A. Chelation therapy in β-thalassemia major. I. Intravenous and subcutaneous deferoxamine. J. Pediatr. 1978; 92: 648
   Google Scholar
• Propper R. D., Cooper B., Rufo R. R., Nienhuis A. W., Anderson W. F., Bunn F. H., Rosenthal A., Nathan D. G. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N. Engl. J. Med. 1977; 297: 418
   PubMed Web of Science ®Google Scholar
• Pippard M. J., Callender S. T., Weatherall D. J. Intensive iron-chelation therapy with desferrioxamine in iron-loading anaemias. Clin. Sci. Mol. Med. 1978; 54: 99
   Google Scholar
• Pippard M. J., Letsky E. A., Callender S. T., Weatherall D. J. Prevention of iron loading in transfusion-dependent thalassaemia. Lancet 1978; 1: 1178
   PubMed Web of Science ®Google Scholar
• Harker L. A., Funk D. D., Finch C. A. Evaluation of storage iron by chelates. Am. J. Med. 1968; 45: 105
   PubMed Web of Science ®Google Scholar
• Silvestroni E., Bianco I., Graziani B., Lerone M., Valente M., Congelo P., Ponzini D., Costantini S. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence. Acta Haematol. 1982; 68: 115
   Google Scholar
• Cohen A., Mizanin J., Schwartz E. Treatment of iron overload in Cooley's anemia. Ann. N.Y. Acad. Sci. 1985; 445: 274
   Google Scholar
• Marcus R. E., Davies S. C., Bantock H. M., Underwood S. R., Walton S., Huehns E. R. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassaemia major. Lancet 1984; 1: 392
   PubMed Web of Science ®Google Scholar
• Weatherall D. J., Pippard M. J., Callender S. T. Iron loading in thalassemia—five years with the pump. N. Engl. J. Med. 1983; 308: 456
   PubMedGoogle Scholar
• Pippard M. J., Callender S. T. The management of iron chelation therapy. Br. J. Haematol. 1983; 54: 503
   PubMed Web of Science ®Google Scholar
• Anon. High-dose chelation therapy in thalassaemia. Lancet 1984; 1: 373
   Google Scholar
• Hyman C. B., Agness C. L., Rodriguez-Funes R., Zednikova M. Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia. Ann. N.Y. Acad. Sci. 1985; 445: 293
   Google Scholar
• Rahko P. S., Salerni R., Uretsky B. F. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J. Am. Coll. Cardiol. 1986; 8: 436
   PubMed Web of Science ®Google Scholar
• Schafer A. I., Rabinowe S., Le Boff M. S., Bridges K., Cheron R. G., Dluhy R. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Arch. Intern. Med. 1985; 145: 1217
   PubMedGoogle Scholar
• Engle M. A., Erlandson M., Smith C. H. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964; 30: 698
   PubMed Web of Science ®Google Scholar
• Engle M. A. Cardiac involvement in Cooley's anemia. Ann. N.Y. Acad. Sci. 1964; 119: 694
   Google Scholar
• Modell B., Letsky E. A., Flynn D. M., Peto R., Weatherall D. J. Survival and desferoxamine in thalassaemia major. Br. Med. J. 1982; 284: 1081
   PubMed Web of Science ®Google Scholar
• Graziano J. H., Piomelli S., Hilgartner M., Giardina P., Karpatkin M., Andrew M., Lo Iacomo N., Seaman C. Chelation therapy in β-thalassaemia major. III. The role of splenectomy in achieving iron balance. J. Pediatr. 1981; 99: 695
   PubMed Web of Science ®Google Scholar
• Wolfe L., Olivieri N., Sallan D., Colan S., Rose V., Propper R., Freedman M. H., Nathan D. G. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N. Engl. J. Med. 1985; 312: 1600
   PubMed Web of Science ®Google Scholar
• Cohen A., Martin M., Schwartz E. Depletion of excessive liver iron stores with desferrioxamine. Br. J. Haematol. 1984; 58: 369
   PubMed Web of Science ®Google Scholar
• Janka G. E., Mohring P., Helmig M., Haas R. J., Betke K. Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload. Eur. J. Pediatr. 1981; 137: 285
   Google Scholar
• Flynn D. M., Hoffbrand A. V., Politis D. Subcutaneous desferrioxamine: the effects of three years' treatment on liver iron, serum ferritin, and comments on echocardiography. Birth Defects Orig. Art. Ser. 1982; 18: 347
   Google Scholar
• Flynn D. M., Fairney A., Jackson D., Clayton B. E. Hormonal changes in thalassaemia major. Arch. Dis. Child. 1976; 51: 828
   PubMed Web of Science ®Google Scholar
• Ehlers K. H., Levin A. R., Markenson A. L., Marcus J. R., Klein A. A., Hilgartner M. W., Engle M. A. Longitudinal study of cardiac function in thalassemia major. Ann. N.Y. Acad. Sci. 1980; 344: 397
   PubMedGoogle Scholar
• Giardina P. J. V., Ehlers K. H., Engle M. A., Grady R. W., Hilgartner M. W. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study. Ann. N.Y. Acad. Sci. 1985; 445: 282
   Google Scholar
• Freeman A. P., Giles R. W., Berdoukas V. A., Walsh W. F., Choy D., Murray P. C. Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann. Intern. Med. 1983; 99: 450
   PubMed Web of Science ®Google Scholar
• Hoffbrand A. V., Gorman A., Laulicht M., Garidi M., Economidou J., Georgipoulou P., Hussain M. A. M., Flynn D. M. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Lancet 1979; 1: 947
   PubMed Web of Science ®Google Scholar
• Cohen A., Martin M., Schwartz E. Response to long-term deferoxamine therapy in thalassemia. J. Pediatr. 1981; 99: 689
   Google Scholar
• Cohen A., Schwartz E. Decreasing iron stores during intensive chelation therapy. Ann. N.Y. Acad. Sci. 1980; 344: 405
   Google Scholar
• Bothwell T. H., Bradlow B. A., Jacobs P., Keeley K., Kramer S., Seftel H., Zail S. Iron metabolism in scurvy with special reference to erythropoiesis. Br. J. Haematol. 1964; 10: 50
   PubMedGoogle Scholar
• Lipschitz D. A., Bothwell T. H., Seftel H. C., Wapnick A. A., Charlton R. W. The role of ascorbic acid in the metabolism of storage iron. Br. J. Haematol. 1971; 20: 155
   PubMed Web of Science ®Google Scholar
• Banerjee S., Chakrabarty A. S. Utilization of iron by scorbutic guinea pigs. Blood 1965; 25: 839
   Google Scholar
• Chapman R. W. G., Hussein M. A. M., Gorman A., Laulicht M., Politis D., Flynn D. M., Sherlock S., Hoffbrand A. V. Effect of ascorbic acid deficiency on serum ferritin concentrations in patients with β-thalassaemia major and iron overload. J. Clin. Pathol. 1982; 35: 487
   PubMed Web of Science ®Google Scholar
• Cohen A., Cohen I. J., Schwartz E. Scurvy and altered iron stores in thalassemia major. N. Engl. J. Med. 1981; 304: 158
   PubMed Web of Science ®Google Scholar
• Lynch S. R., Seftel H. C., Torrance J. D., Charlton R. W., Bothwell T. H. Accelerated oxidative catabolism of ascorbic acid in siderotic Bantu. Am. J. Clin. Nutr. 1967; 20: 641
   PubMed Web of Science ®Google Scholar
• O'Brien R. T. Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major. Ann. N.Y. Acad. Sci. 1974; 232: 221
   PubMed Web of Science ®Google Scholar
• Bridges K. R., Hoffman K. E. The effects of ascorbic acid on the intracellular metabolism of iron and ferritin. J. Biol. Chem. 1986; 261: 14273
   PubMed Web of Science ®Google Scholar
• Nienhuis A. W. Vitamin C and iron. N. Engl. J. Med. 1981; 304: 170
   PubMed Web of Science ®Google Scholar
• Henry W. Echocardiography evaluation of the heart in thalassemia major. Ann. Intern. Med. 1979; 91: 892
   Google Scholar
• Rowbotham B., Roeser H. P. Iron overload associated with congenital pyruvate kinase deficiency and high dose ascorbic acid ingestion. Aust. N.Z. J. Med. 1984; 14: 667
   PubMedGoogle Scholar
• McClaren C. J., Bett J. H. N., Nye J. A., Halliday J. W. Congestive cardiomyopathy and hemochromatosis—rapid progression possibly accelerated by excessive ingestion of ascorbic acid. Aust. N.Z. J. Med. 1982; 12: 187
   Google Scholar
• Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts is a feasible source of hydroxyl radicals in vivo. J. Biochem. 1982; 205: 461
   Google Scholar
• Sirivech S., Frieden E., Osaki S. The release of iron from horse spleen ferritin by reduced flavins. Biochem. J. 1974; 143: 311
   PubMed Web of Science ®Google Scholar
• Nakamoto S., Yamanoi Y., Kawabata T., Sadahira Y., Mori M., Awai M. Lipid peroxidation and cytotoxicity of Ehrlich ascites tumor cells by ferric nitriloacetate. Biochim. Biophys. Acta 1986; 889: 15
   Google Scholar
• Heys A. D., Dormandy T. L. Lipid peroxidation in iron-overloaded spleens. Clin. Sci. 1981; 60: 295
   Web of Science ®Google Scholar
• Miller K. B., Rosenwasser L. J., Bessette J. M., Beer D. J., Rocklin R. E. Rapid desensitization for desferrioxamine anaphylactic reaction. Lancet 1981; 1: 1059
   Google Scholar
• Bloomfield S. E., Markenson A. L., Miller D. R., Peterson C. M. Lens opacities in thalassemia. J. Ped. Ophtholmol. Strab. 1978; 15: 154
   Web of Science ®Google Scholar
• Davies S. C., Hungerford J. L., Arden J. B., Marcus R. E., Miller M. H., Huehns E. R. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983; 2: 181
   PubMed Web of Science ®Google Scholar
• Rahi A. H. S., Hungerford J. L., Ahmed A. Ocular toxicity of desferrioxamine: light microscopic, histochemical and ultrastructural findings. Br. J. Ophtholmol. 1986; 70: 373
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C., De Stefano P., Broglia A. M. Visual loss in a patient on high-dose subcutaneous desferrioxamine. Lancet 1984; 1: 681
   PubMedGoogle Scholar
• Olivieri N. F., Buncic J. R., Chew E., Gallant T., Harrison R. V., Keenan N., Logan W., Mitchell D., Ricci G., Skarf B., Taylor M., Freedman M. H. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N. Engl. J. Med. 1986; 314: 869
   PubMed Web of Science ®Google Scholar
• Polson R. J., Jawed A., Bomford A., Berry H., Williams R. Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects. Br. Med. J. 1985; 291: 448
   Google Scholar
• Blake D. R., Winyard P., Lunec J., Williams A., Good P. A., Crewes A. J., Gutteridge J. M. C., Rowley D., Halliwell B., Cornish A., Hider R. C. Central and ocular toxicity induced by desferrioxamine. Q. J. Med. 1985; 56: 345
   PubMedGoogle Scholar
• Rubinstein M., Dupont P., Doppee J. P., Dehon C., Ducobu J., Hainaut J. Ocular toxicity of desferrioxamine. Lancet 1985; 1: 817
   PubMed Web of Science ®Google Scholar
• Simon P., Ang K. S., Meyvier A., Allain P., Mauras Y. Desferrioxamine, ocular toxicity, and trace metals. Lancet 1983; 2: 512
   Google Scholar
• Arden G. B. Desferrioxamine administered intravenously by infusion causes a loss of retinal sensitivity in rabbits anesthetised with urethane, submitted
   Google Scholar
• Robins-Browne R. M., Prpic J. K. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infect. Immun. 1985; 47: 774
   PubMed Web of Science ®Google Scholar
• Gallant T., Freedman M. H., Vellend H., Francombe W. H. Yersinia sepsis in patients with iron overload treated with deferoxamine. N. Engl. J. Med. 1986; 314: 1643
   PubMed Web of Science ®Google Scholar
• Calescibetta C. C., Eribaum A. I., Coburn J. W. Fatal disseminated phycomycosis (mucormycosis) in patients on deferoxamine for aluminium toxicity (Abstr.). Am. J. Kidney Dis. 1986; 8: A20
   Google Scholar
• Goodill J. J., Abuelo J. G. Mucormycosis—a new risk of deferoxamine therapy in dialysis patients with aluminum or iron overload?. N. Engl. J. Med. 1987; 317: 54
   PubMed Web of Science ®Google Scholar
• Halliwell B., Gutteridge J. M. C. Oxygen, free radicals and iron in relation to biology and medicine: some problems and concepts. Arch. Biochem. Biophys. 1986; 246: 5401
   Google Scholar
• Johnson K. J., Fantone J. C., Kaplan J., Ward P. A. In vivo damage of rat lungs by oxygen metabolites. J. Clin. Invest. 1981; 67: 983
   PubMed Web of Science ®Google Scholar
• Gutteridge J. M. C., Richmond R., Halliwell B. Inhibition of the iron-catalysed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine. Biochem. J. 1979; 184: 469
   PubMed Web of Science ®Google Scholar
• Blake D. R., Hall N. D., Bacon P. A., Dieppe P. A., Halliwell B., Gutteridge J. M. C. The importance of iron in rheumatoid disease. Lancet 1981; 2: 1142
   PubMed Web of Science ®Google Scholar
• Betts W. H., Cleland L. G. Effect of metal chelators and antiinflammatory drugs on the degradation of hyaluronic acid. Arthritis Rheum. 1982; 25: 1469
   PubMedGoogle Scholar
• Winyard P. G., Blake D. R., Chirico S., Gutteridge J. M. C., Lunec J. Mechanism of exacerbation of rheumatoid synovitis by total-dose iron-dextran infusion: in-vivo demonstration of iron-promoted oxidant stress. Lancet 1987; 1: 69
   PubMed Web of Science ®Google Scholar
• Blake D. R., Hall N. D., Bacon P. A., Dieppe P. A., Halliwell B., Gutteridge J. M. C. Effect of a specific iron chelating agent on animal models of inflammation. Ann. Rheum. Dis. 1983; 42: 89
   PubMed Web of Science ®Google Scholar
• Polson R. J., Jawad A. S. M., Bomford A., Berry H., Williams R. Treatment of rheumatoid arthritis with desferrioxamine. Q. J. Med. 1986; 61: 1153
   PubMedGoogle Scholar
• Giordano N., Fioravanti A., Sancasciani S., Marcolongo R., Borghi C. Increased storage of iron and anaemia in rheumatoid arthritis: usefulness of desferrioxamine. Br. Med. J. 1984; 289: 961
   PubMed Web of Science ®Google Scholar
• Ward P. A., Till G. O., Kunkel R., Beauchamps C. Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J. Clin. Invest. 1983; 72: 789
   PubMed Web of Science ®Google Scholar
• Fligiel S. E. G., Ward P. A., Johnson K. J., Till G. O. Evidence for a role of hydroxyl radical in immune-complex-induced vasculitis. Am. J. Pathol. 1984; 115: 375
   PubMedGoogle Scholar
• Cochrane C. G., Spragg R., Revak S. D. Pathogenesis of the adult respiratory distress syndrome: evidence of oxidant activity in bronchoalveolar lavage fluid. J. Clin. Invest. 1983; 71: 754
   PubMed Web of Science ®Google Scholar
• Baldwin S. R., Grum C. M., Boxer L. A., Simon R. H., Ketai L. H., Devall L. J. Oxidant activity in expired breath of patients with adult respiratory distress syndrome. Lancet 1986; 1: 11
   PubMed Web of Science ®Google Scholar
• White B. C., Krause G. S., Aust S. D., Eyster G. E. Postischemic tissue injury by iron-mediated free radical lipid peroxidation. Ann. Emerg. Med. 1985; 14: 804
   PubMed Web of Science ®Google Scholar
• Nayini N. R., White B. C., Aust S. D., Huang R. R., Indieri R. J., Evans A. T., Bialek H., Jacobs W. A., Komara J. Post resuscitation iron delocalization and malondialdehyde production in the brain following prolonged cardiac arrest. J. Free Radical Biol. Med. 1985; 1: 111
   PubMedGoogle Scholar
• Fleischer J. E., Lanier W. L., Milde J. H., Michenfelder J. D. Failure of deferoxamine, an iron chelator, to improve neurologic outcome following complete cerebral ischemia in dogs. Stroke 1987; 18: 124
   PubMed Web of Science ®Google Scholar
• Badylak S. F., Babbs C. F. The effect of carbon dioxide, lidoflazine and deferoxamine upon long term survival following cardiorespiratory arrest in rats. Resuscitation 1986; 13: 165
   Google Scholar
• Babbs C. F. Role of iron ions in the genesis of reperfusion injury following successful cardiopulmonary resuscitation: preliminary data and a biochemical hypothesis. Ann. Emerg. Med. 1985; 14: 777
   PubMed Web of Science ®Google Scholar
• Green J. C., Healing G., Simpkin S., Lunec J., Fuller B. J. Increased susceptibility to lipid peroxidation in rabbit kidneys: a consequence of warm ischaemia and subsequent reperfusion. J. Comp. Biochem. Physiol. 1986; 83: 603
   Google Scholar
• Green C. J., Healing G., Simpkin S., Fuller B. J., Lunec J. Reduced susceptibility to lipid peroxidation in cold ischemic rabbit kidneys after addition of desferrioxamine, mannitol and uric acid to the flush solution. Cryobiology 1986; 23: 358
   PubMed Web of Science ®Google Scholar
• Bradley B., Prowse S. J., Bauling P., Lafferty K. J. Desferrioxamine treatment prevents chronic islet allograft damage. Diabetes 1986; 35: 550
   PubMed Web of Science ®Google Scholar
• Weinberg K., Champagne J., Lenarsky C., Peterson J., Nguyen T., Felder B., Parkman R. Desferrioxamine (DFO) inhibition of interleukin 2 receptor (IL2R) expression: potential therapy of graft versus host disease (GVHD) (Abstr.). Blood 1986; 68(Suppl. 1)286a
   Google Scholar
• Chandler D. B., Fulwer J. D. The effect of deferoxamine on bleomycin-induced lung fibrosis in the hamster. Am. Rev. Respir. Dis. 1985; 131: 596
   PubMed Web of Science ®Google Scholar
• Cross C. E., Warren D., Gerriets J. E., Wilson D. W., Halliwell B., Last J. A. Deferoxamine injection does not affect bleomycin-induced lung fibrosis in rats. J. Lab. Clin. Med. 1985; 106: 433
   PubMedGoogle Scholar
• Kohen R., Chevion M. Paraquat toxicity is enhanced by iron and reduced by desferrioxamine in laboratory mice. Biochem. Pharmacol. 1985; 34: 1841
   PubMed Web of Science ®Google Scholar
• Osheroff M. R., Schaich K. M., Drew R. T., Borg D. C. Failure of desferrioxamine to modify the toxicity of paraquat in rats. J. Free Radical Biol. Med. 1985; 1: 71
   PubMedGoogle Scholar
• Hershko C., Karsai A., Eylon L., Izak G. The effect of chronic iron deficiency on some biochemical functions of the human hemopoietic tissue. Blood 1970; 36: 321
   PubMedGoogle Scholar
• Joynson D. H. M., Jacobs A., Murray-Walker D., Dolby A. E. Defect of cell-mediated immunity in patients with iron-deficiency anaemia. Lancet 1972; 2: 1058
   PubMed Web of Science ®Google Scholar
• Lederman H. M., Cohen A., Lee J. W. W., Freedman M. H., Gelfand E. W. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984; 64: 748
   PubMed Web of Science ®Google Scholar
• Hoffbrand A. V., Ganeshaguru K., Hooton J. W. L., Tattersall M. H. N. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br. J. Haematol. 1976; 33: 517
   PubMed Web of Science ®Google Scholar
• Reichard P., Ehrenberg A. Ribonucleotide reductase—a radical enzyme. Science 1983; 221: 514
   PubMed Web of Science ®Google Scholar
• Estrow Z., Tawa A., Wang X. H., Dube I. D., Sulh H., Cohen A., Gelfand E. W., Freedman M. H. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987; 69: 757
   Google Scholar
• Raventos-Suarez C., Pollack S., Nagel R. L. Plasmodium falciparum: inhibition of in vitro growth by desferrioxamine. Am. J. Trop. Med. Hyg. 1982; 31: 919
   PubMed Web of Science ®Google Scholar
• Peto T. E. A., Thompson J. L. A reappraisal of the effects of iron and desferrioxamine on the growth of Plasmodium falciparum in vitro: the unimportance of serum iron. Br. J. Haematol. 1986; 63: 273
   PubMed Web of Science ®Google Scholar
• Fritch G., Treumer J., Spira D. T., Jung A. Plasmodium vinckei: suppression of mouse infections with desferrioxamine B. Exp. Pathol. 1985; 60: 171
   Google Scholar
• Pollack S., Rossan R. N., Davidson D. E., Escajadillo A. Desferrioxamine suppresses Plasmodium falciparum in aotus monkeys. Proc. Soc. Exp. Biol. Med. 1987; 184: 162
   PubMed Web of Science ®Google Scholar
• Kushner J. P., Steinmuller D. P., Lee G. R. The role of iron in the pathogenesis of porphyria cutanea tarda. II. Inhibition of uroporphyrinogen decarboxylase. J. Clin. Invest. 1979; 56: 661
   Google Scholar
• Ramsay C. A., Magnus I. A., Turnbull A., Baker H. The treatment of porphyria cutanea tarda by venesection. Q. J. Med. 1974; 43: 1
   PubMedGoogle Scholar
• Rocchi E., Gilbertini P., Cassanelli M., Pietrangelo A., Borghi A., Pantaleoni M., Jensen J., Ventura E. Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion. Br. J. Dermatol. 1986; 114: 621
   PubMed Web of Science ®Google Scholar
• Praga M., de Salamanca R. E., Andres A., Nieto J., Oliet A., Perpina J., Morales J. M. Treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine. N. Engl. J. Med. 1987; 316: 547
   Google Scholar
• Martell A. E. The design and synthesis of chelating agents. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North-Holland, Amsterdam 1981; 67
   Google Scholar
• Neilands J. B. Microbial iron transport compounds (siderophores) as chelating agents. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North-Holland, Amsterdam 1981; 13
   Google Scholar
• Jacobs A. Screening for iron chelating drugs. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North-Holland, Amsterdam 1981; 39
   Google Scholar
• White G. P., Jacobs A., Grady R. W., Cerami A. The use of chang cells cultured in vitro to evaluate potential iron chelating drugs. Br. J. Haematol. 1976; 33: 487
   PubMed Web of Science ®Google Scholar
• Porter J. B., Gyparaki M., Huehns E. R., Hider R. C. The relationship between lipophilicity of hydroxypyrid-4-one iron chelators and cellular iron mobilization, using a hepatocyte culture model. Biochem. Soc. Trans. 1986; 14: 1180
   Google Scholar
• Baker E., Richardson D., Gross S., Wong A., Grady R. W., Ponka P., Hider R., Kontoghiorghes G., Peter H., Nozoe S. Evaluation of new iron chelators in the hepatocyte in culture (Abstr.). 8th Int. Conf. Proteins of Iron Transport and Storage, Le Chateau Montebello, Canada, May, 10 to 141987, 143
   Google Scholar
• Grady R. W., Jacobs A. The screening of potential iron chelating drugs. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North-Holland, Amsterdam 1981; 133
   Google Scholar
• Pitt C. G., Gupta G., Estes W. E., Rosenkrantz H., Metterville J. J., Crumbliss A. L., Palmer R. A., Nordquest K. W., Hardy Sprinkle K. A., Whitcomb D. R., Byers B. R., Arceneaux J. E. L., Gaines C. G., Sciortino C. V. The selection and evaluation of new chelating agents for the treatment of iron overload. J. Pharmacol. Exp. Ther. 1979; 208: 12
   PubMed Web of Science ®Google Scholar
• Hershko C., Grady R. W., Link G. Phenolic ethylenediamine derivatives: a study of orally effective iron chelators. J. Lab. Clin. Med. 1984; 103: 337
   PubMed Web of Science ®Google Scholar
• Gyparaki M., Porter J. B., Hirani S., Streater M., Hider R. C., Huehns E. R. In vivo evaluation of hydroxypyridone iron chelators in a mouse model. Acta Haematol.
   Google Scholar
• Pippard M. J., Johnson D. K., Finch C. A. A rapid assay for evaluation of iron-chelating agents in rats. Blood 1981; 58: 685
   Google Scholar
• Pitt C. G. Structure and activity relationships of iron chelating drugs. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier/North-Holland, Amsterdam 1981; 105
   Google Scholar
• Cerami A., Grady R. W., Peterson C. M., Bhargava K. The status of new iron chelators. Ann. N.Y. Acad. Sci. 1980; 344: 425
   Google Scholar
• Kontoghiorghes G. J. Orally active α-ketohydroxypyridone iron chelators: studies in mice. Mol. Pharmacol. 1986; 30: 670
   PubMed Web of Science ®Google Scholar
• Atkin C. L., Neilands J. B. Rhodotorulic acid, a diketopiperazine dihydroxamic acid with growth-factor activity. I. Isolation and characterization. Biochemistry 1968; 7: 3734
   PubMed Web of Science ®Google Scholar
• Grady R. W., Graziano J. H., White G. P., Jacobs A., Cerami A. The development of new iron chelating drugs. II. J. Pharmacol. Exp. Ther. 1978; 205: 757
   Google Scholar
• Hershko C., Grady R. W., Cerami A. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization. J. Lab. Clin. Med. 1978; 92: 144
   Google Scholar
• Grady R. W., Peterson C. M., Jones R. L., Graziano J. H., Bhargava K. K., Berdoukas V. A., Kokkini G., Loukopolos D., Cerami A. Rhodotorulic acid—investigation of its potential as an iron-chelating drug. J. Pharmacol. Exp. Ther. 1979; 209: 342
   PubMed Web of Science ®Google Scholar
• Winston A., Varaprasad D. V. P. R., Metterville J. J., Rosenkrantz H. Evaluation of polymeric hydroxamic acid iron chelators for treatment of iron overload. J. Pharmacol. Exp. Ther. 1985; 232: 644
   PubMed Web of Science ®Google Scholar
• Peterson C. M., Graziano J. H., Grady R. W., Jones R. L., Markenson A., Lavi U., Canale V., Gray G. F., Cerami A., Miller D. R. Chelation therapy in β-thalassemia major: a one-year double blind study of 2,3-dihydroxybenzoic acid. Exp. Hematol. 1979; 7: 74
   PubMed Web of Science ®Google Scholar
• Harris W. R., Weitl F. L., Raymond K. N. Synthesis and evaluation of an enterobactin model compound. 1,3,5-Tris (2,3-dihydroxybenzoylaminomethyl)-benzene and its iron (III) complex. J.C.S. Chem. Commun. 1979; 177: 178
   Google Scholar
• Venuti M. C., Rasletter W. H., Neilands J. B. 1,3,5-Tris (N,N'N”-2,3-dihyroxybenzoyl) aminomethylbenzene, a synthetic iron chelator related to enterobactin. J. Med. Chem. 1979; 22: 123
   PubMed Web of Science ®Google Scholar
• Fahey J. L., Roth C. E., Princiotto J. V., Brick I. B., Rubin M. Evaluation of trisodium calcium diethylenetriamine pentaacetate in iron storage disease. J. Lab. Clin. Med. 1961; 57: 436
   PubMedGoogle Scholar
• Frost A. E., Freedman H. H., Westerback S. J., Martell A. E. Chelating tendencies of N,N'-ethylenebis ‘2-(o-hydroxyphenyl)’-glycine. J. Am. Chem. Soc 1958; 80: 530
   Web of Science ®Google Scholar
• L'Eplattenier F., Murase I., Martell A. E. New multidentate ligands. VI. Chelating tendencies of N,N'-Di(2-hydroxybenzoyl)ethylenediamine-N,N'-diacetic acid. J. Am. Chem. Soc. 1967; 89: 837
   Web of Science ®Google Scholar
• Martell A. E., Motekaitis R. J. PLED, a new chelating ligand for the treatment of β-thalassemia. Inorg. Chim. Acta 1983; 79: 295
   Google Scholar
• Hershko C., Grady R. W., Link G. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug. Br. J. Haematol. 1982; 51: 251
   PubMed Web of Science ®Google Scholar
• Cleton F., Turnbull A., Finch C. A. Synthetic chelating agents in iron metabolism. J. Clin. Invest. 1963; 42: 327
   Google Scholar
• Rosenkrantz H., Metterville J. J., Fleischman R. W. Preliminary toxicity findings in dogs and rodents given the iron chelator ethylenediamine-N,Nbis(2-hydroxyphenylacetic acid) (EDHPA). Fundam. Appl. Toxicol. 1986; 6: 292
   PubMedGoogle Scholar
• Stifel F. B., Better R. L. Effect of a synthetic chelating agent upon forage intake and ruminal fermentation in lambs. J Anim. Sci. 1967; 26: 126
   Google Scholar
• Ponka P., Borova J., Neuwirth J., Fuchs O. Mobilization of iron from reticulocytes. FEBS Lett. 1970; 97: 317
   Google Scholar
• Ponka P., Borova J., Neuwirth J., Fuchs O., Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta 1979; 586: 278
   PubMed Web of Science ®Google Scholar
• Hershko C., Avramovici-Grisaru S., Link G., Gelfand L., Sarel S. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J. Lab. Clin. Med. 1981; 98: 99
   PubMed Web of Science ®Google Scholar
• Hoy T., Humphrys J., Jacobs A., Williams A., Ponka P. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br. J. Haematol. 1979; 43: 443
   PubMed Web of Science ®Google Scholar
• Johnson D. K., Pippard M. J., Murphy T. B., Rose N. J. An in vivo evaluation of iron chelating drugs derived from pyridoxal and its analogs. J. Pharmacol. Exp. Ther. 1982; 221: 399
   PubMed Web of Science ®Google Scholar
• Brown E. B. Candidate chelating drugs: where do we stand?. Development of Iron Chelators for Clinical Use, A. E. Martell, W. F. Anderson, D. G. Badman. Elsevier North/Holland, Amsterdam 1981; 47
   Google Scholar
• Williams A., Hoy T., Pugh A., Jacobs A. Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overload. J. Pharm. Pharmacol. 1982; 34: 730
   PubMed Web of Science ®Google Scholar
• Cook J. D., Hershko C., Finch C. A. Storage iron kinetics. V. Iron exchange in the rat. Br. J. Haematol. 1973; 25: 695
   PubMed Web of Science ®Google Scholar
• Avramovici-Grisaru S., Sarel S., Link G., Hershko C. Synthesis of pyridoxal isonicotinoyl hydrazones and the in vivo iron-removal properties of some pyridoxal derivatives. J. Med. Chem. 1983; 26: 298
   PubMed Web of Science ®Google Scholar
• Hershko C., Link G., Pinson A., Sarel S., Grisaru S., Hasin Y., Grady R. W. Iron toxicity and chelating therapy. Proc. 6th Int. Symp. Trace Elements in Man and Animals. Plenum Press, New York 1987
   Google Scholar
• Kontoghiorghes G. J., Hoffbrand A. V. Orally active β-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits. Br. J. Haematol. 1986; 62: 607
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes G. J. New orally active iron chelators. Lancet. 1985; 1: 817
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes G. J. Dose response studies using desferr ioxamine and orally active chelators in a mouse model. Scand. J. Haematol. 1986; 37: 63
   Google Scholar
• Kontoghiorghes G. J., Chambers S., Hoffbrand A. V. Comparative study of iron mobilization from haemosiderin, ferritin and iron III precipitates by chelators. Biochem. J. 1987; 241: 87
   PubMed Web of Science ®Google Scholar
• Gyparaki M., Porter J. B., Huehns E. R., Hider R. C. Evaluation in vivo of hydroxypyrid-4-one iron chelators intended for the treatment of iron overload by the oral route. Biochem. Soc. Trans. 1986; 14: 1181
   Google Scholar
• Gyparaki M., Hider R. C., Huehns E. R., Porter J. B. Hydroxypyridone iron chelators: in vitro and in vivo evaluation, chap. 5. Thalassemia Today. The Mediterranean Experience, G. Sirchia, A. Zanella, Milano 1987; 521, Centre Transf. Osped. Maggione, Policlin. di Milano Editore
   Google Scholar
• Kontoghiorghes G. J., Aldhouri M. A., Sheppard L., Hoffbrand A. V. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally effective chelator for the treatment of iron overload. Lancet. 1987; 1: 1294
   PubMed Web of Science ®Google Scholar
• Naegeli H. U., Zahner H. Stoffwechsel Produkte von Mikroorganismen—Ferrithiocin. Helv. Chim. Acta. 1980; 63: 1400
   Web of Science ®Google Scholar
• Peter H. H. Eisenchelierung. Schweiz. Med. Wschr. 1983; 113: 1428
   Google Scholar
• Longueville A., Crichton R. R. An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators. Biochem. Pharmacol. 1986; 35: 3669
   PubMed Web of Science ®Google Scholar
• Pippard M. J., Jackson M. J., Hoffman K., Petrou M., Modell C. B. Iron chelation using subcutaneous infusion of diethylene triamine pema-acetic acid (DTPA). Scand. J. Haematol. 1986; 36: 466
   PubMedGoogle Scholar
• Hussain M. A. M., Flynn D. M., Green N., Hussein S., Hoffbrand A. V. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet. 1976; 2: 1278
   PubMed Web of Science ®Google Scholar
• Hussain M. A. M., Flynn D. M., Green N., Hoffbrand A. V. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine. Lancet. 1977; 1: 977
   PubMed Web of Science ®Google Scholar
• Arden G. B., Wonke B., Kennedy C., Huehns E. R. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br. J. Ophthalmol. 1984; 68: 873
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes G. K., Aldouri M. A., Hoffbrand A. V., Barr J., Wonke B., Kourouclaris T., Sheppard L. Effective chelation of iron in β-thalassaemia with the oral chelator 1,2-dimethyl- 3-hydroxypyrid-4-one. Br. Med. J. 1987; 295: 1509
   PubMed Web of Science ®Google Scholar
• Mark J. J. M., personal communication
   Google Scholar